Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results

Explore Xeris Biopharma Holdings's Fair Values from the Community and select yours

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) just released its latest quarterly results and things are looking bullish. The results overall were pretty good, with revenues of US$72m exceeding expectations and statutory losses coming in at justUS$0.01 per share, some 69% below what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Xeris Biopharma Holdings after the latest results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the latest results, the five analysts covering Xeris Biopharma Holdings are now predicting revenues of US$281.4m in 2025. If met, this would reflect a notable 14% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 78% to US$0.043. Before this earnings announcement, the analysts had been modelling revenues of US$268.8m and losses of US$0.078 per share in 2025. So it seems there's been a definite increase in optimism about Xeris Biopharma Holdings' future following the latest consensus numbers, with a considerable decrease in the loss per share forecasts in particular.

Check out our latest analysis for Xeris Biopharma Holdings

It will come as no surprise to learn thatthe analysts have increased their price target for Xeris Biopharma Holdings 24% to US$7.80on the back of these upgrades. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Xeris Biopharma Holdings analyst has a price target of US$11.00 per share, while the most pessimistic values it at US$6.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Xeris Biopharma Holdings' revenue growth is expected to slow, with the forecast 31% annualised growth rate until the end of 2025 being well below the historical 44% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 7.9% annually. So it's pretty clear that, while Xeris Biopharma Holdings' revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that in mind, we wouldn't be too quick to come to a conclusion on Xeris Biopharma Holdings. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Xeris Biopharma Holdings going out to 2027, and you can see them free on our platform here..

We don't want to rain on the parade too much, but we did also find 1 warning sign for Xeris Biopharma Holdings that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.